Sangamo Therapeutics, Inc.
SGMO • NASDAQ
Sangamo Therapeutics, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Alexander D. Macrae Ch.B, with a market cap of $119.3M.
CEOAlexander D. Macrae Ch.B
Next Earnings
Upcoming earnings announcement for Sangamo Therapeutics, Inc.
Date
Monday, May 11, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.04
Revenue Estimate
$18.9M
Earnings History
Past 11 earnings reports for Sangamo Therapeutics, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Nov 6, 2025 | Q3 2025 | -$0.11Est: -$0.07 | -57.1% | $581.0KEst: $40.6M | -98.6% |  10-Q |
| Aug 7, 2025 | Q2 2025 | -$0.08Est: -$0.10 | +20.0% | $18.3MEst: $27.1M | -32.4% | 10-Q |
| May 12, 2025 | Q1 2025 | -$0.14Est: -$0.13 | -7.7% | $6.4MEst: $7.4M | -13.2% | 10-Q |
| Mar 17, 2025 | Q4 2024 | -$0.11Est: -$0.09 | -22.2% | $7.6MEst: $15.9M | -52.5% | 10-K |
| Nov 12, 2024 | Q3 2024 | $0.04Est: -$0.03 | +233.3% | $49.4MEst: $17.9M | +175.4% | 10-Q |
| Aug 6, 2024 | Q2 2024 | -$0.18Est: -$0.15 | -20.0% | $356.0KEst: $8.3M | -95.7% | 10-Q |
| May 9, 2024 | Q1 2024 | -$0.27Est: -$0.21 | -28.6% | $481.0KEst: $6.7M | -92.8% | 10-Q |
| Mar 13, 2024 | Q4 2023 | -$0.34Est: -$0.26 | -30.8% | $2.0MEst: $8.1M | -74.8% | 10-K |
| Nov 1, 2023 | Q3 2023 | -$0.59Est: -$0.32 | -84.4% | $9.4MEst: $10.4M | -9.6% | — |
| Aug 8, 2023 | Q2 2023 | -$0.37Est: -$0.34 | -8.8% | $6.8MEst: $14.8M | -53.9% | 10-Q |
| Apr 26, 2023 | Q1 2023 | $0.12Est: -$0.33 | +136.4% | $158.0MEst: $24.1M | +556.5% | 10-Q |